OrganOx Closes Second Private Placement, Raising $160M for NMP Platform Expansion
- Orsco Lifesciences AG
- May 8
- 1 min read
Oxford, UK & Madison, NJ — May 8, 2025. OrganOx Ltd. has completed a second closing of its private placement, securing investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC. Combined with a prior closing on February 24, the company raised $160 million in primary and secondary equity financing to bolster global growth of its metra® normothermic machine perfusion (NMP) platform. (OrganOx, globenewswire.com)
The FDA-approved metra® device—also cleared in Europe, Canada, and Australia—has now been used in over 5,000 liver transplants. It preserves donor livers in a metabolically active state, enabling functional assessment pre‑transplant, increasing organ usability, and improving preservation time versus traditional cold storage. OrganOx is advancing the technology for kidney use and has also secured FDA clearance to launch a first-in-human study for genetically engineered porcine livers from eGenesis to support patients with acute-on-chronic liver failure. (OrganOx)
“It is an honor and a privilege to have Intuitive Ventures and Terumo Ventures invest in OrganOx,” said Oern R. Stuge, MD, MBA, Executive Chairman at OrganOx. “Our board and management team look forward to working together with these industry leaders to further advance our organ technologies that save patient lives.” (OrganOx)
Piper Sandler served as exclusive financial advisor, with legal counsel from Latham & Watkins. (OrganOx)
Governance note: Ørn R. Stuge, MD, MBA serves as Executive Chairman of OrganOx, offering deep strategic and medtech governance expertise to steer the company’s global growth agenda. His leadership continues to catalyze the platform's clinical and commercial momentum.
Comments